Downregulation of plasma SELENBP1 protein in patients with recent-onset schizophrenia

EJ Chau; MS Mostaid; V Cropley; P McGorry; C Pantelis; CA Bousman; IP Everall

Journal article

Downregulation of plasma SELENBP1 protein in patients with recent-onset schizophrenia

EJ Chau, MS Mostaid, V Cropley, P McGorry, C Pantelis, CA Bousman, IP Everall

Progress in Neuro Psychopharmacology and Biological Psychiatry | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2018

DOI: 10.1016/j.pnpbp.2018.03.010

Abstract

Upregulation of selenium binding protein 1 (SELENBP1) mRNA expression has been reported in schizophrenia, primarily in the dorsolateral prefrontal cortex. However, peripheral blood studies are limited and results are inconsistent. In this study, we examined SELENBP1 mRNA expression in whole blood and protein expression in plasma from patients with recent-onset schizophrenia (n = 30), treatment-resistant schizophrenia (n = 71) and healthy controls (n = 57). We also examined the effects of SELENBP1 genetic variation on gene and protein expression. We found lower SELENBP1 plasma protein levels in patients with recent-onset schizophrenia (p = 0.042) but not in treatment-resistant schizophrenia (..

View full abstract

University of Melbourne Researchers

Vanessa Cropley Author

Patrick McGorry Author

Christos Pantelis Author

Related Projects (2)

RESEARCH FELLOWSHIP - PROF CHRISTOS PANTELIS

I have established and head the Melbourne Neuropsychiatry Centre within the University of Melbourne. My university position is a research ch..

NEUROBIOLOGICAL 'RISK' AND 'RESILIENCE' BIOMARKERS OF SEVERE MENTAL ILLNESS

Mental disorders of childhood (schizotypal disorder, autism spectrum disorders) and adolescence (psychoses, schizophrenia) represent a major..

Grants

Awarded by Brain and Behavior Research Foundation

Funding Acknowledgements

The authors acknowledge the financial support of the CRC for Mental Health. The Cooperative Research Centre (CRC) program is an Australian Government Initiative. The authors also wish to acknowledge the CRC Scientific Advisory Committee, in addition to the contributions of study participants, clinicians at recruitment services, staff at the Murdoch Children's Research Institute, staff at the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Aging, and research staff at the Melbourne Neuropsychiatry Centre, including coordinators Phassouliotis, C., Merritt, A., and research assistants, Burnside, A., Cross, H., Gale, S., and Tahtalian, S. Participants for this study were sourced, in part, through the Australian Schizophrenia Research Bank (ASRB), which is supported by the National Health and Medical Research Council of Australia (Enabling Grant N. 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation and the Schizophrenia Research Institute. We thank the Chief Investigators and ASRB Manager: Carr, V., Schall, U., Scott, R., Jablensky, A., Mowry, B., Michie, P., Catts, S., Henskens, F., Pantelis, C., Loughland, C. We acknowledge the help of "Jason Bridge for ASRB database queries."MM was supported by a Cooperative Research Centre for Mental Health Top-up Scholarship. CP was supported by an NHMRC Senior Principal Research Fellowship (628386 & 1105825), and a Brain and Behavior Research Foundation (NARSAD) Distinguished Investigator Award. CAB was supported by a NHMRC Career Development Fellowship (1127700). None of the funding sources played any role in the study design; collection, analysis or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.